Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to face off with Ozempic maker Novo Nordisk. Eli Lilly said in a news release that its orforglipron pill had passed a Phase 3 trial with “statistically significant efficacy results” and a safety profile consistent with injectable obesity drugs that already are on the market.

Eli Lilly shares are now positive for the year, up 10% since the start of January.

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily obesity pill, orforglipron, met company goals in the first of several late-stage trials — helping patients with Type 2 diabetes lower their blood sugar while causing weight loss.